Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Publication/Presentation Date
1-2024
Published In/Presented At
Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. JCO 42, 106-106(2024).
DOI:10.1200/JCO.2024.42.3_suppl.106Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS